Pyrimethamine

Malaria is a vector-borne infectious disease that seriously threatens the health of people in tropical and subtropical regions around the world. The R&D and supply of antimalarial drugs have always been one of the core topics in the field of public health. Pyrimethamine is an antimalarial drug belonging to the dihydrofolate reductase inhibitor class. It inhibits the dihydrofolate reductase of Plasmodium, blocks its nucleic acid synthesis, and thus inhibits the schizont proliferation of Plasmodium. Clinically, it is mainly used for the etiological prevention of malaria, and can also be used in combination with sulfonamides or sulfones to treat chloroquine-resistant falciparum malaria. The applicable population includes permanent residents and floating population in malaria-endemic areas, as well as epidemic prevention and migrant workers with high exposure risk.

The global antimalarial drug market size has maintained steady growth all year round. In 2023, the overall size has exceeded 18 billion US dollars, of which prophylactic antimalarial drugs account for about 17%. As a core component of the basic antimalarial drug combination, pyrimethamine is an essential drug for global malaria prevention and control reserves, with relatively rigid demand. Due to the early launch time of this drug, the global market is dominated by generic drug supply, and the main production areas are concentrated in major generic drug producing countries such as China and India. At present, there is no relevant collective procurement winning record for pyrimethamine in China.

The original research enterprise of pyrimethamine is GlaxoSmithKline, with the original brand name Daraprim. The core compound patent expired globally in the 1970s. The main dosage form of the original research product is tablet, with a specification of 25mg, which has been included in the FDA Reference Listed Drug Catalog. As of October 2024, no pyrimethamine API registered with A status has been found in the database of the Center for Drug Evaluation of the National Medical Products Administration. A small number of pyrimethamine tablet preparations have been approved for marketing in China, most of which are produced by domestic pharmaceutical enterprises. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for pyrimethamine API, which can cover the testing needs of the whole process from R&D to application for approval. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide stable support for the product R&D and quality control of relevant pharmaceutical enterprises.